Breast cancer prevention trials: Large and small trials

Seminars in Oncology

Volumn 37, Issue 4, 2010, Pages 367-383

  Arun, Banu ^a   Dunn, Barbara K ^b   Ford, Leslie G ^b   Ryan, Anne ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BEXAROTENE; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CELECOXIB; EFLORNITHINE; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; PLACEBO; RALOXIFENE; RISEDRONIC ACID; ROFECOXIB; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADJUVANT THERAPY; ANGINA PECTORIS; ARTHRALGIA; BREAST; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CARDIOVASCULAR DISEASE; CATARACT; CLINICAL TRIAL; COLORECTAL ADENOMA; DEATH; DEEP VEIN THROMBOSIS; DRUG DESIGN; DRUG TARGETING; ENDOMETRIUM CANCER; FRAGILITY FRACTURE; HEART INFARCTION; HIP FRACTURE; HOT FLUSH; HUMAN; ISCHEMIA; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL PAIN; OSTEOPOROSIS; OUTCOME ASSESSMENT; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SIDE EFFECT; SPINE FRACTURE; STROKE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; UTERUS CANCER; VAGINA DISCHARGE; VENOUS THROMBOEMBOLISM; WRIST FRACTURE; BREAST NEOPLASMS; CLINICAL TRIAL (TOPIC); FEMALE; PATHOLOGY;

BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS;

EID: 77956361950     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2010.05.004     Document Type: Article

References (86)

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
2. M.D. Althuis, J.H. Fergenbaum, M. Garcia-Closas, L.A. Brinton, M.P. Madigan, and M.E. Sherman Etiology of hormone receptor-defined breast cancer: a systematic review of the literature Cancer Epidemiol Biomarkers Prev 13 2004 1558 1568
3. P.M. Ravdin, K.A. Cronin, and N. Howlader The decrease in breast-cancer incidence in 2003 in the United States N Engl J Med 356 2007 1670 1674
4. J.E. Rossouw, G.L. Anderson, and R.L. Prentice Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial JAMA 288 2002 321 333
5. B. Fisher, J.P. Costantino, and D.L. Wickerham Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 90 1998 1371 1388
6. V.G. Vogel, J.P. Costantino, D.L. Wickerham, W.M. Cronin, and N. Wolmark The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial Clin Breast Cancer 3 2002 153 159
7. S.G. Nayfield, J.E. Karp, L.G. Ford, F.A. Dorr, and B.S. Kramer Potential role of tamoxifen in prevention of breast cancer J Natl Cancer Inst 83 1991 1450 1459
8. Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer: an overview of the randomised trials Lancet 351 1998 1451 1467
9. Early Breast Cancer Trialists' Collaborative Group Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 2005 1687 1717
10. B.K. Dunn, and L.G. Ford From adjuvant therapy to breast cancer prevention: BCPT and STAR Breast J 7 2001 144 157
11. T. Powles, R. Eeles, and S. Ashley Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial Lancet 352 1998 98 101
12. U. Veronesi, P. Maisonneuve, and A. Costa Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women Italian Tamoxifen Prevention Study Lancet 352 1998 93 97
13. J. Cuzick, J. Forbes, and R. Edwards First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial Lancet 360 2002 817 824
14. J. Cuzick, J.F. Forbes, and I. Sestak Long-term results of tamoxifen prophylaxis for breast cancer96-month follow-up of the randomized IBIS-I trial J Natl Cancer Inst 99 2007 272 282
15. J. Cuzick, T. Powles, and U. Veronesi Overview of the main outcomes in breast-cancer prevention trials Lancet 361 2003 296 300
16. M.H. Gail, J.P. Costantino, and J. Bryant Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer J Natl Cancer Inst 91 1999 1829 1846
17. J. Eng-Wong, and J.A. Zujewski Raloxifene and its role in breast cancer prevention Expert Rev Anticancer Ther 4 2004 523 532
18. S.R. Cummings, S. Eckert, and K.A. Krueger The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial Multiple Outcomes of Raloxifene Evaluation JAMA 281 1999 2189 2197
19. B. Ettinger, D.M. Black, and B.H. Mitlak Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators JAMA 282 1999 637 645
20. V.G. Vogel, J.P. Costantino, and D.L. Wickerham Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 295 2006 2727 2741
21. M.H. Gail, L.A. Brinton, and D.P. Byar Projecting individualized probabilities of developing breast cancer for white females who are being examined annually J Natl Cancer Inst 81 1989 1879 1886
22. FDA News FDA approves new uses for Evista drug reduces risk of invasive breast cancer in postmenopausal women http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/2007/ucm108981.htm September 14, 2007 Last accessed March 31, 2010
23. V. Vogel, J. Costantino, and D.L. Wickerham Update of the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer Cancer Prev Res (Phila Pa) 3 2010 696 706
24. C.I. Herold, and K.L. Blackwell Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease Clin Breast Cancer 8 2008 50 64
25. J. Cuzick Aromatase inhibitors in early breast-cancer treatment: the story so far Breast 17 Suppl 3 2008 S2 S8
26. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial Lancet 359 2002 2131 2139
27. I. Sestak, F. Sapunar, and J. Cuzick Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial J Clin Oncol 27 2009 4961 4965
28. S.R. Duffy, W. Distler, A. Howell, J. Cuzick, and M. Baum A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial Am J Obstet Gynecol 200 2009 80 e1-7
29. A. Buzdar, A. Howell, and J. Cuzick Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial Lancet Oncol 7 2006 633 643
30. R. Jakesz, W. Jonat, and M. Gnant Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial Lancet 366 2005 455 462
31. F. Boccardo, A. Rubagotti, and M. Puntoni Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial J Clin Oncol 23 2005 5138 5147
32. W. Jonat, M. Gnant, and F. Boccardo Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis Lancet Oncol 7 2006 991 996
33. J. Cuzick Aromatase inhibitors in preventiondata from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study) Recent Results Cancer Res 163 2003 96 103
34. J. Cuzick Aromatase inhibitors for breast cancer prevention J Clin Oncol 23 2005 1636 1643
35. J. Cuzick Chemoprevention of breast cancer Breast Cancer 15 2008 10 16
36. IBIS-II study http://www.ibis-trials.org/index.php Last accessed April 12, 2010
37. R.C. Coombes, E. Hall, and L.J. Gibson A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 2004 1081 1092
38. R.C. Coombes, L.S. Kilburn, and C.F. Snowdon Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial Lancet 369 2007 559 570
39. R.E. Coleman, L.M. Banks, and S.I. Girgis Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study Lancet Oncol 8 2007 119 127
40. P.E. Goss, S. Qi, A.M. Cheung, H. Hu, M. Mendes, and K.P. Pritzker Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats Clin Cancer Res 10 2004 5717 5723
41. P.E. Goss, S. Qi, and R.G. Josse The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats Bone 34 2004 384 392
42. H. Richardson, D. Johnston, J. Pater, and P. Goss The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial Curr Oncol 14 2007 89 96
43. Phase III randomized study of exemestane in postmenopausal women at increased risk of developing breast cancer http://www.cancer.gov/clinicaltrials/ CAN-NCIC-MAP3 Last accessed November 5, 2009
44. D. Hwang, D. Scollard, J. Byrne, and E. Levine Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer J Natl Cancer Inst 90 1998 455 460
45. E. Half, X.M. Tang, K. Gwyn, A. Sahin, K. Wathen, and F.A. Sinicrope Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ Cancer Res 62 2002 1676 1681
46. S.A. Khuder, and A.B. Mutgi Breast cancer and NSAID use: a meta-analysis Br J Cancer 84 2001 1188 1192
47. R.S. Bresalier, R.S. Sandler, and H. Quan Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial N Engl J Med 352 2005 1092 1102
48. P.E. Goss, H. Richardson, R. Chlebowski, D. Johnston, G.E. Sarto, and E. Maunsell National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: evaluation of exemestane to prevent breast cancer in postmenopausal women Clin Breast Cancer 7 2007 895 900
49. P.E. Goss, J.N. Ingle, and S. Martino A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer N Engl J Med 349 2003 1793 1802
50. P.E. Goss, J.N. Ingle, and S. Martino Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17 J Natl Cancer Inst 97 2005 1262 1271
51. P.E. Goss, J.N. Ingle, and J.L. Pater Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen J Clin Oncol 26 2008 1948 1955
52. B. Thurlimann, A. Keshaviah, and A.S. Coates A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer N Engl J Med 353 2005 2747 2757
53. A.S. Coates, A. Keshaviah, and B. Thurlimann Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98 J Clin Oncol 25 2007 486 492
54. E. Marshall Cancer research Budget pressure puts high-profile study in doubt Science 315 2007 1477
55. NCI and the STELLAR trial Lancet 369 2007 2134
56. The next generation of breast cancer prevention: clinical trial background for NSABP P-4 http://www.bresatcancerprevention.org/stellar.html Last accessed May 29, 2008
57. A.H. Partridge, A. LaFountain, E. Mayer, B.S. Taylor, E. Winer, and A. Asnis-Alibozek Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer J Clin Oncol 26 2008 556 562
58. P.P. Donnellan, S.L. Douglas, D.A. Cameron, and R.C. Leonard Aromatase inhibitors and arthralgia J Clin Oncol 19 2001 2767
59. K.D. Crew, H. Greenlee, and J. Capodice Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer J Clin Oncol 25 2007 3877 3883
60. L. Morales, S. Pans, and K. Verschueren Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome J Clin Oncol 26 2008 3147 3152
61. M. Baum, A. Buzdar, and J. Cuzick Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses Cancer 98 2003 1802 1810
62. A. Howell, J. Cuzick, and M. Baum Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 2005 60 62
63. J.F. Forbes, J. Cuzick, A. Buzdar, A. Howell, J.S. Tobias, and M. Baum Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial Lancet Oncol 9 2008 45 53
64. J. Cuzick IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole Expert Rev Anticancer Ther 8 2008 1377 1385
65. Dunn BK, Jegalian K, Greenwald P. Biomarkers for early detection and as surrogate endpoints in cancer prevention trials: Issues and opportunities. In: Senn H-J, Otto F, editors. Recent Results in Cancer Research. Clinical Cancer Prevention. Berlin/New York/London: Springer Books; in press.
66. B.K. Dunn, and L.G. Ford Breast cancer prevention: results of the National Surgical Adjuvant Breast and Bowel Project (NSABP) breast cancer prevention trial (NSABP P-1: BCPT) Eur J Cancer 36 Suppl 4 2000 S49 S50
67. C. Rubino, R. Arriagada, S. Delaloge, and M.G. Le Relation of risk of contralateral breast cancer to the interval since the first primary tumour Br J Cancer 102 2010 213 219
68. G.J. Kelloff, S.M. Lippman, and A.J. Dannenberg Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancera plan to move forward Clin Cancer Res 12 2006 3661 3697
69. C.J. Fabian, B.F. Kimler, M.S. Mayo, and S.A. Khan Breast-tissue sampling for risk assessment and prevention Endocr Relat Cancer 12 2005 185 213
70. B. Arun, V. Valero, and C. Logan Comparison of ductal lavage and random periareolar fine needle aspiration as tissue acquisition methods in early breast cancer prevention trials Clin Cancer Res 13 2007 4943 4948
71. C.J. Fabian, B.F. Kimler, and D.A. Brady A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers Clin Cancer Res 8 2002 3105 3117
72. S.E. Singletary, E.N. Atkinson, and A. Hoque Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia Clin Cancer Res 8 2002 2835 2842
73. V. Stearns, A. Coop, and B. Singh A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasia Clin Cancer Res 10 2004 7583 7591
74. S.K. Mohsin, D.C. Allred, and C.K. Osborne Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancer Breast Cancer Res Treat 94 2005 205 211
75. B. Arun, C. Logan, and V. Valero Chemoprevention trial of celecoxib in women at increased risk for breast cancer Proc Am Soc Clin Oncol 25 2007 abstract 1501
76. C.J. Fabian, B.F. Kimler, and C.M. Zalles Reduction in proliferation with six months of letrozole in women on hormone replacement therapy Breast Cancer Res Treat 106 2007 75 84
77. P.H. Brown, B. Arun, and A.B. Miller Phase II trial of bexarotene in women at high risk of breast cancer: comparison of protein and RNA biomarkers (abstract CN04-04) November 16-19, 2008 AACR Frontiers in Cancer Prevention Washington, DC
78. S.R. Cummings, B. Ettinger, and P.D. Delmas The effects of tibolone in older postmenopausal women N Engl J Med 359 2008 697 708
79. S.R. Cummings, K. Ensrud, and P.D. Delmas Lasofoxifene in postmenopausal women with osteoporosis N Engl J Med 362 2010 686 696
80. M. Gnant, B. Mlineritsch, and W. Schippinger Endocrine therapy plus zoledronic acid in premenopausal breast cancer N Engl J Med 360 2009 679 691
81. R.E. Coleman Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy? Eur J Cancer 45 2009 1909 1915
82. D. Mauri, A. Valachis, and N.P. Polyzos Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials J Natl Compr Cancer Netw 8 2010 279 286
83. Y. Li, and P.H. Brown Prevention of ER-negative breast cancer Recent Results Cancer Res 181 2009 121 134
84. S. Wacholder, P. Hartge, and R. Prentice Performance of common genetic variants in breast-cancer risk models N Engl J Med 362 2010 986 993
85. K. Kerlikowske, L. Ichikawa, and D.L. Miglioretti Longitudinal measurement of clinical mammographic breast density to improve estimation of breast cancer risk J Natl Cancer Inst 99 2007 386 395
86. V. Brower Breast density gains acceptance as breast cancer risk factor J Natl Cancer Inst 102 2010 374 375